【醫藥護人員場】活動議程
-
00:00
1.
Novel Life-Prolonging Endocrine Therapies for Metastatic CRPC
-
00:52
2.
CRPC Definition (2016 EAU Guidelines)
-
01:32
3.
Androgen Receptor Signaling - A Pivotal Driver of Prostate Cancer
-
02:03
4.
Phase III Trials in mCRPC with OS Advantage
-
03:54
5.
Systemic Therapy for M0 CRPC
-
04:19
6.
Systemic Therapy for M1 CRPC
-
04:30
7.
Subsequent Systemic Therapy for M1 CRPC
-
05:03
8.
Traditional Hormonal Therapy for CRPCAddition of Anti-androgens
-
05:24
9.
Traditional Hormonal Therapy for CRPCAnti-androgen Withdrawal
-
05:36
10.
Traditional Hormonal Therapy for CRPCCorticosteroids / Estrogens
-
05:46
11.
Traditional Hormonal Therapy for CRPCCorticosteroids / Estrogens
-
06:16
12.
Traditional Hormonal Therapy for CRPCKetoconazole
-
06:23
13.
mCRPC Management: EAU Guideline (Update 2016)
-
07:20
14.
mCRPC Management: EAU Guideline (Update 2016)
-
07:43
15.
24. Metastatic CRPC: First Line Treatment: Asymptomatic /Minimally Symptomatic Patients
-
08:14
16.
25. Metastatic CRPC: First Line Treatment Symptomatic Patients
-
08:50
17.
Targeting the Androgen Pathway
-
09:19
18.
Abiraterone Acetate (Zytiga) : Androgen Biosynthesis (CYP17) Inhibitor
-
10:12
19.
Abiraterone Increases Steroids with Mineralocorticoid Activity Upstream of CYP17A1
-
10:38
20.
COU-AA-301 Post-Chemo Study Design
-
10:54
21.
COU-AA-301: Abiraterone Significantly Prolongs OS and rPFS in Post-docetaxel mCRPC Patients
-
11:01
22.
COU-AA-302 Pre-Chemo Study Design
-
11:29
23.
COU-AA-302: Radiographic PFS and OS
-
11:38
24.
COU-AA-302: Pre-specified Secondary and Exploratory Efficacy End Points
-
12:50
25.
COU-AA-302: Safety Profile Remains Consistent
-
13:10
26.
Incidence of Mineralocorticoid Excess (ME)-Associated Treatment-Emergent Adverse Events (TEAE)
-
13:55
27.
Study Design and Timelines
-
14:39
28.
Primary Endpoint: Patients Experiencing ME-Associated TEAEs: Hypertension and Hypokalemia
-
14:57
29.
Confirmed PSA Response Rate (≥50%) after 12 Weeks
-
15:14
30.
61. When to Discontinue Life-prolonging Treatment (Excluding treatment change for toxicity)
-
16:14
31.
What if PSA does not Decline following Abiraterone ?
-
17:11
32.
Slide 33
-
17:37
33.
Enzalutamide (Xtandi, MDV3100): A New Anti-androgenAndrogen Receptor Signaling Inhibitor (ARSI)
-
18:30
34.
Phase III Enzalutamide (MDV-3100) vs Placeboin Post-chemotherapy Treated CRPC
-
18:53
35.
AFFIRM: Enzalutamide Prolongs OS and PFS
-
19:10
36.
AFFIRM: Response and Progression Indicators
-
19:23
37.
AFFIRM: Safety Outcomes
-
19:54
38.
Phase III Pre-chemotherapy Enzalutamide (MDV3100) Prostate Cancer Trial (PREVAIL)
-
20:05
39.
PREVAIL Co-Primary Endpoints: Radiographic PFS and OS for Final and Extended Analysis
-
20:43
40.
Subsequent Therapies were Used More Commonly in the Placebo Group
-
21:13
41.
Enzalutamide (PREVAIL):Important Secondary Endpoints
-
21:23
42.
PREVAIL: Most Common AE* and AEs of Interest
-
21:29
43.
Slide 47
-
21:41
44.
PREVAIL: rPFS and OS in the Non-visceral & Visceral Subgroup
-
21:55
45.
PREVAIL: rPFS and OS by Number of Bone Mets at Screening
-
22:05
46.
Inclusion/Exclusion Criteria of the Pivotal Trials
-
23:04
47.
Second-line Treatment Options in mCRPCComparison of the Efficacy Results in the TROPIC, COU-AA-301 and AFFIRM trials
-
23:20
48.
Primary Resistance & Predictive Factors in mCRPC
-
24:00
49.
Slide 53
-
24:30
50.
Primary Resistance to AR-Targeted Agents
-
24:59
51.
Slide 55
-
25:59
52.
Slide 56
-
26:33
53.
Duration of Response to First ADT May Help to Guide Treatment Choice?
-
27:19
54.
Is Baseline Gleason Score Predictive of Response to Therapies?
-
28:32
55.
PSA Response According to ARv7 Status
-
29:07
56.
ARv7 and Resistance to ABI or ENZ:Clinical or Radiological PFS
-
29:19
57.
ARv7 and Resistance to ABI or ENZ – Updated OS (All Combined)
-
29:47
58.
Treatment Sequencing in mCRPC
-
30:43
59.
Evidences of Earlier Use of Novel Endocrine Therapies in Metastatic CRPC Patients
-
31:10
60.
Slide 64
-
31:17
61.
TERRAIN: A Study of Enzalutamide vs Bicalutamide in Men with Metastatic CRPC
-
32:12
62.
TERRAIN: PFS and Radiographic PFS
-
32:22
63.
TERRAIN: Pre-specified Subgroup Analysis of PFS
-
32:38
64.
TERRAIN: Time to PSA Progression
-
32:47
65.
TERRAIN: Safety Overview
-
33:00
66.
STRIVE: A Study of Enzalutamide vs Bicalutamide in Men with Prostate Cancer Who Failed Primary ADT
-
33:21
67.
The STRIVE Trial: Results
-
33:46
68.
Longer Time to PSA Progression in CRPC Patients Treated with Enzalutamide Earlier
-
35:10
69.
Slide 75
-
36:04
70.
ARN-509 blocks AR signaling, impairs AR nuclear translocation and inhibits DNA binding
-
36:17
71.
Slide 84
-
36:33
72.
Combination Trials
-
36:39
73.
ALLIANCE Study Design Phase III Pre-chemo
-
37:21
74.
PLATO: Continued enzalutamide treatment in prostate cancer patients
-
37:52
75.
Combination Phase III Study Design of ARN-509 andAbiraterone (n ~ 960)
-
39:03
76.
Key Consideration for Treatment Sequencing
-
40:19
77.
Thank You for Your Attentions
- 索引
- 筆記
- 全螢幕
【醫藥護人員場】12. Novel Life-Prolonging Endocrine Therapies for Metastatic Castration-Resistant Prostate Cancer
長度: 41:28, 瀏覽: 1452, 最近修訂: 2017-05-09
-
00:00
1.
Novel Life-Prolonging Endocrine Therapies for Metastatic CRPC
-
00:52
2.
CRPC Definition (2016 EAU Guidelines)
-
01:32
3.
Androgen Receptor Signaling - A Pivotal Driver of Prostate Cancer
-
02:03
4.
Phase III Trials in mCRPC with OS Advantage
-
03:54
5.
Systemic Therapy for M0 CRPC
-
04:19
6.
Systemic Therapy for M1 CRPC
-
04:30
7.
Subsequent Systemic Therapy for M1 CRPC
-
05:03
8.
Traditional Hormonal Therapy for CRPCAddition of Anti-androgens
-
05:24
9.
Traditional Hormonal Therapy for CRPCAnti-androgen Withdrawal
-
05:36
10.
Traditional Hormonal Therapy for CRPCCorticosteroids / Estrogens
-
05:46
11.
Traditional Hormonal Therapy for CRPCCorticosteroids / Estrogens
-
06:16
12.
Traditional Hormonal Therapy for CRPCKetoconazole
-
06:23
13.
mCRPC Management: EAU Guideline (Update 2016)
-
07:20
14.
mCRPC Management: EAU Guideline (Update 2016)
-
07:43
15.
24. Metastatic CRPC: First Line Treatment: Asymptomatic /Minimally Symptomatic Patients
-
08:14
16.
25. Metastatic CRPC: First Line Treatment Symptomatic Patients
-
08:50
17.
Targeting the Androgen Pathway
-
09:19
18.
Abiraterone Acetate (Zytiga) : Androgen Biosynthesis (CYP17) Inhibitor
-
10:12
19.
Abiraterone Increases Steroids with Mineralocorticoid Activity Upstream of CYP17A1
-
10:38
20.
COU-AA-301 Post-Chemo Study Design
-
10:54
21.
COU-AA-301: Abiraterone Significantly Prolongs OS and rPFS in Post-docetaxel mCRPC Patients
-
11:01
22.
COU-AA-302 Pre-Chemo Study Design
-
11:29
23.
COU-AA-302: Radiographic PFS and OS
-
11:38
24.
COU-AA-302: Pre-specified Secondary and Exploratory Efficacy End Points
-
12:50
25.
COU-AA-302: Safety Profile Remains Consistent
-
13:10
26.
Incidence of Mineralocorticoid Excess (ME)-Associated Treatment-Emergent Adverse Events (TEAE)
-
13:55
27.
Study Design and Timelines
-
14:39
28.
Primary Endpoint: Patients Experiencing ME-Associated TEAEs: Hypertension and Hypokalemia
-
14:57
29.
Confirmed PSA Response Rate (≥50%) after 12 Weeks
-
15:14
30.
61. When to Discontinue Life-prolonging Treatment (Excluding treatment change for toxicity)
-
16:14
31.
What if PSA does not Decline following Abiraterone ?
-
17:11
32.
Slide 33
-
17:37
33.
Enzalutamide (Xtandi, MDV3100): A New Anti-androgenAndrogen Receptor Signaling Inhibitor (ARSI)
-
18:30
34.
Phase III Enzalutamide (MDV-3100) vs Placeboin Post-chemotherapy Treated CRPC
-
18:53
35.
AFFIRM: Enzalutamide Prolongs OS and PFS
-
19:10
36.
AFFIRM: Response and Progression Indicators
-
19:23
37.
AFFIRM: Safety Outcomes
-
19:54
38.
Phase III Pre-chemotherapy Enzalutamide (MDV3100) Prostate Cancer Trial (PREVAIL)
-
20:05
39.
PREVAIL Co-Primary Endpoints: Radiographic PFS and OS for Final and Extended Analysis
-
20:43
40.
Subsequent Therapies were Used More Commonly in the Placebo Group
-
21:13
41.
Enzalutamide (PREVAIL):Important Secondary Endpoints
-
21:23
42.
PREVAIL: Most Common AE* and AEs of Interest
-
21:29
43.
Slide 47
-
21:41
44.
PREVAIL: rPFS and OS in the Non-visceral & Visceral Subgroup
-
21:55
45.
PREVAIL: rPFS and OS by Number of Bone Mets at Screening
-
22:05
46.
Inclusion/Exclusion Criteria of the Pivotal Trials
-
23:04
47.
Second-line Treatment Options in mCRPCComparison of the Efficacy Results in the TROPIC, COU-AA-301 and AFFIRM trials
-
23:20
48.
Primary Resistance & Predictive Factors in mCRPC
-
24:00
49.
Slide 53
-
24:30
50.
Primary Resistance to AR-Targeted Agents
-
24:59
51.
Slide 55
-
25:59
52.
Slide 56
-
26:33
53.
Duration of Response to First ADT May Help to Guide Treatment Choice?
-
27:19
54.
Is Baseline Gleason Score Predictive of Response to Therapies?
-
28:32
55.
PSA Response According to ARv7 Status
-
29:07
56.
ARv7 and Resistance to ABI or ENZ:Clinical or Radiological PFS
-
29:19
57.
ARv7 and Resistance to ABI or ENZ – Updated OS (All Combined)
-
29:47
58.
Treatment Sequencing in mCRPC
-
30:43
59.
Evidences of Earlier Use of Novel Endocrine Therapies in Metastatic CRPC Patients
-
31:10
60.
Slide 64
-
31:17
61.
TERRAIN: A Study of Enzalutamide vs Bicalutamide in Men with Metastatic CRPC
-
32:12
62.
TERRAIN: PFS and Radiographic PFS
-
32:22
63.
TERRAIN: Pre-specified Subgroup Analysis of PFS
-
32:38
64.
TERRAIN: Time to PSA Progression
-
32:47
65.
TERRAIN: Safety Overview
-
33:00
66.
STRIVE: A Study of Enzalutamide vs Bicalutamide in Men with Prostate Cancer Who Failed Primary ADT
-
33:21
67.
The STRIVE Trial: Results
-
33:46
68.
Longer Time to PSA Progression in CRPC Patients Treated with Enzalutamide Earlier
-
35:10
69.
Slide 75
-
36:04
70.
ARN-509 blocks AR signaling, impairs AR nuclear translocation and inhibits DNA binding
-
36:17
71.
Slide 84
-
36:33
72.
Combination Trials
-
36:39
73.
ALLIANCE Study Design Phase III Pre-chemo
-
37:21
74.
PLATO: Continued enzalutamide treatment in prostate cancer patients
-
37:52
75.
Combination Phase III Study Design of ARN-509 andAbiraterone (n ~ 960)
-
39:03
76.
Key Consideration for Treatment Sequencing
-
40:19
77.
Thank You for Your Attentions
- 位置
-
- 資料夾名稱
- 2016臺大攝護祭-醫藥護人員場
- 發表人
- 系統管理者
- 單位
- 泌尿部
- 建立
- 2016-05-10 12:38:00
- 最近修訂
- 2017-05-09 09:58:19
- 長度
- 41:28